Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly
CNBC • • general
Key Points:
- Novo Nordisk's stock dropped 15% after its next-generation weight loss drug, CagriSema, failed to demonstrate non-inferiority to Eli Lilly's tirzepatide in an 84-week trial.
- CagriSema achieved a 23% weight loss at a 2.4 mg dose compared to 25.5% with a 15 mg dose of tirzepatide, falling short of the primary endpoint.
- Despite the setback, Novo Nordisk plans further trials with higher-dose combinations, aiming to explore the full potential of CagriSema, which combines semaglutide and cagrilintide.
- Eli Lilly's stock rose 3.5% in
